- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03298659
iFR Guided Multi-vessel Revascularization During Percutaneous Coronary Intervention for Acute Myocardial Infarction (iMODERN)
Instantaneous Wave-free Ratio Guided Multi-vessel revascularizatiOn During Percutaneous Coronary intervEntion for Acute myocaRdial iNfarction (iMODERN)
In patients with acute ST-elevation myocardial infarction (STEMI), 40-60% have multi-vessel disease with an increased cardiovascular morbidity and mortality. Although it is not recommended to revascularize noninfarct lesions during the acute intervention, recent investigations suggest the opposite and show improved outcome after direct revascularization of noninfarct lesions. It is undesirable to risk procedure-related complications by treating noninfarct lesions without impaired flow. It is currently unknown whether pressure guided revascularization of noninfarct lesions in the acute phase improves outcome compared to the current guidelines.
The iMODERN trial aims to compare an iFR-guided intervention of noninfarct lesions during the acute intervention with a deferred stress perfusion CMR-guided strategy during the outpatient follow-up, to determine the optimal therapeutic approach for STEMI patients with multivessel lesions.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study design:
The study is a prospective, randomized controlled, multicentre study.
Study population:
The research population will be recruited from the general patient population presenting with an acute STEMI. Patients treated with successful primary PCI and one or more additional significant coronary lesions in another coronary artery will be enrolled in the study. A total of 1,146 consecutive patients will be included.
Intervention:
The patients will be randomized 1:1, to (A) an active treatment arm with complete, iFR-guided revascularization of every noninfarct coronary lesion >50% and iFR ≤0.89; (B) a deferred treatment arm, in which patients will undergo an adenosine stress perfusion CMR scan within 6 weeks after STEMI, with revascularization of the noninfarct coronary lesions with associated perfusion defects.
Main study parameters/endpoints:
The primary end point consists of a combined outcome, including all-cause death, recurrent MI and hospitalization for heart failure at 3 years follow-up.
Duration:
Anticipated recruitment is 2 years. Follow-up will be performed at 6 months, 12 months, 3 years and 5 years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Robin Nijveldt, MD
- Phone Number: +31243614533
- Email: Robin@Nijveldt.net
Study Contact Backup
- Name: Stefaan Van der Meulen, MSc
- Phone Number: +32477984154
- Email: svandermeulen@syntactx.com
Study Locations
-
-
-
Nijmegen, Netherlands
- Radboudumc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinical presentation of STEMI and successful primary PCI within 12 hours from onset of symptoms.
- One or more other, noninfarct coronary artery lesions of >50% stenosis and feasible to be revascularized (i.e. minimal diameter 2mm).
Exclusion Criteria:
- History of myocardial infarction.
- Hemodynamic instability, respiratory failure, Kilips class ≥III.
- Known GFR<30 ml/min.
- Known contra-indications for stress CMR (e.g.: severe claustrophobia, metal implants, severe renal failure, severe astma).
- Refusal or inability to provide informed consent.
- Life expectancy due to noncardiovascular co-morbidity of less than 12 months.
- Chronic total occlusion.
- Left main stem stenosis (>50%).
- Residual noninfarct lesion in infarct coronary artery.
- Complex (e.g. bifurcation) noninfarct target lesions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active iFR-guided revascularization
Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment
|
Treatment guided by instantaneous wave-free ratio
|
Active Comparator: Deferred CMR-guided revascularization
Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
|
Treatment guided by stress perfusion CMR
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite end point of Major Adverse Cardiac Events
Time Frame: 3 years
|
All-cause death, recurrent myocardial infarction and hospitalization for heart failure
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All cause mortality
Time Frame: 6 and 12 months, 3 and 5 years
|
All cause mortality at 6 and 12 months, 3 and 5 years
|
6 and 12 months, 3 and 5 years
|
Cardiovascular mortality
Time Frame: 6 and 12 months, 3 and 5 years
|
Cardiovascular mortality at 6 and 12 months, 3 and 5 years
|
6 and 12 months, 3 and 5 years
|
Myocardial infarction
Time Frame: 6 and 12 months, 3 and 5 years
|
Myocardial infarction at 6 and 12 months, 3 and 5 years
|
6 and 12 months, 3 and 5 years
|
Cerebral events
Time Frame: 6 and 12 months, 3 and 5 years
|
Stroke and transient ischemic attack
|
6 and 12 months, 3 and 5 years
|
Major bleeding
Time Frame: 6 months
|
Haemorrhagic complications
|
6 months
|
Unstable angina
Time Frame: 6 and 12 months, 3 and 5 years
|
Unstable angina including ECG-changes at 6 and 12 months, 3 and 5 years
|
6 and 12 months, 3 and 5 years
|
Coronary angiography
Time Frame: 6 and 12 months, 3 and 5 years
|
Coronary angiography at 6 and 12 months, 3 and 5 years
|
6 and 12 months, 3 and 5 years
|
Revascularization
Time Frame: 6 and 12 months, 3 and 5 years
|
Any revascularization at 6 and 12 months, 3 and 5 years
|
6 and 12 months, 3 and 5 years
|
Target lesion failure
Time Frame: 6 and 12 months, 3 and 5 years
|
Failure and/or revascularization by percutaneous or surgical methods of the target lesion
|
6 and 12 months, 3 and 5 years
|
Stent thrombosis
Time Frame: 6 and 12 months, 3 and 5 years
|
Stent thrombosis at 6 and 12 months, 3 and 5 years
|
6 and 12 months, 3 and 5 years
|
Cost effectiveness analysis
Time Frame: 6 and 12 months, 3 and 5 years
|
Costs related to complete, iFR-guided revascularization versus CMR-guided treatment, including cost utility analysisfrom a societal perspective with the costs per prevented cardiac eventand the costs per QALY as the respective primary health economic outcomes (using a quality of life questionnaire and a health care resource use questionnaire)
|
6 and 12 months, 3 and 5 years
|
Quality of life
Time Frame: 6 and 12 months, 3 and 5 years
|
Quality of life questionnaires, i.e.
SAQ, EQ-5D-5L and Minnesota heart failure questionnaire, at 6 and 12 months, 3 and 5 years
|
6 and 12 months, 3 and 5 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Ong P, Martinez Pereyra V, Sechtem U, Bekeredjian R. Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022? Coron Artery Dis. 2022 Sep 1;33(6):485-489. doi: 10.1097/MCA.0000000000001157. Epub 2022 Jul 11.
- Beijnink CWH, Thim T, van der Heijden DJ, Klem I, Al-Lamee R, Vos JL, Koop Y, Dijkgraaf MGW, Beijk MAM, Kim RJ, Davies J, Raposo L, Baptista SB, Escaned J, Piek JJ, Maeng M, van Royen N, Nijveldt R. Instantaneous wave-free ratio guided multivessel revascularisation during percutaneous coronary intervention for acute myocardial infarction: study protocol of the randomised controlled iMODERN trial. BMJ Open. 2021 Jan 15;11(1):e044035. doi: 10.1136/bmjopen-2020-044035.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL60107.029.16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myocardial Infarction
-
Henry Ford Health SystemAbiomed Inc.Enrolling by invitationAcute Myocardial Infarction | Cardiogenic Shock | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial Infarction | NSTEMI | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction of Right Ventricle (Disorder) | Acute Myocardial Infarction of Left VentricleUnited States
-
Jordan Collaborating Cardiology GroupCardiovascular Academy GroupTerminatedTriggers of Acute Myocardial Infarction | Time of Onset of Acute Myocardial Infarction | Long-term Prognosis After Acute Myocardial InfarctionJordan
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
Medical Center of South ArkansasWithdrawnAcute Coronary Syndrome | Acute ST Segment Elevation Myocardial InfarctionUnited States
-
Yuan's General HospitalKaohsiung Veterans General Hospital.; Sin-Lau HospitalUnknownAcute Myocardial Infarction, of Inferolateral Wall | Acute Myocardial Infarction, of Inferoposterior WallTaiwan
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Acute Coronary Syndrome | Acute Myocardial Infarction | Metabolic DisturbanceGreece
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Sheba Medical CenterCompletedNon ST Elevation Myocardial Infarction | Acute Coronary SyndromesIsrael
-
Medstar Health Research InstituteWithdrawnST-elevation Myocardial Infarction | Acute Myocardial InfarctionUnited States
-
Hennepin Healthcare Research InstituteSiemens HealthineersActive, not recruitingAcute Coronary Syndrome | Acute Myocardial InfarctionUnited States
Clinical Trials on iFR
-
Volcano CorporationDuke Clinical Research Institute; Cardiovascular Research Foundation, New YorkCompletedCoronary Artery Disease | Angina, Stable | Angina, Unstable | Coronary StenosisUnited States, Netherlands, United Kingdom
-
Uppsala UniversityCompletedAngina Pectoris | Acute Myocardial InfarctionSweden, Denmark, Iceland
-
Imperial College LondonUnknownCoronary Artery DiseaseUnited States, United Kingdom, Spain, Australia, Belgium, Egypt, Finland, Germany, Italy, Japan, Korea, Republic of, Latvia, Netherlands, Portugal, Saudi Arabia, South Africa, Turkey
-
Kobe UniversityUnknownCoronary Artery Disease | Aortic Valve Stenosis
-
Contilia Clinical Research InstituteUnknownCoronary Artery Disease | Fractional Flow Reserve, MyocardialGermany
-
Azienda Ospedaliera San Camillo ForlaniniUnknownST Segment Elevation Myocardial InfarctionItaly
-
Instituto Dante Pazzanese de CardiologiaFundação de Amparo à Pesquisa do Estado de São PauloRecruitingCoronary Artery Disease Left MainBrazil
-
Maimónides Biomedical Research Institute of CórdobaActive, not recruitingInstantaneous Wave Free Ratio | Diffuse Coronary Artery Disease | Long Coronary Lesion | Syncvision SoftwareSpain
-
Volcano CorporationCompletedCoronary DiseaseBelgium
-
The Cleveland ClinicVolcano CorporationTerminatedAortic Stenosis | Coronary Artery StenosesUnited States